



Market Announcement

19 August 2021

Noxopharm Limited (ASX: NOX) – Trading Halt

Description

The securities of Noxopharm Limited ('NOX') will be placed in trading halt at the request of NOX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 23 August 2021 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)



Date: 19 August 2021

Sydney, Australia

Ms Melissa Kostopoulos
Compliance Adviser
Listings Compliance (Melbourne)
ASX Compliance Pty Limited
Level 4 Rialto North Tower
525 Collins Street
Melbourne VIC 3000

By Email: tradinghaltsmelbourne@asx.com.au

Dear Melissa,

NOXOPHARM LIMITED – TRADING HALT

The Company requests a trading halt effective immediately allowing the Company to seek external advice on the data contained in the pending release of an announcement relating to an update on the Company's NOXCOVID Clinical Program and Veyonda® drug candidate ("NOXCOVID Update").

The trading halt is requested until the earlier of the release of an announcement relating to the Company's NOXCOVID Update or prior to the opening of trading on Monday 23rd August 2021.

The Company is not aware of any reason why the trading halt should not be granted.

Thank you for your assistance. If you have any questions please contact the Company Secretary, David Franks on 0414 899 897.

Yours faithfully,

A handwritten signature in black ink, appearing to read "D. Franks".

David Franks
Company Secretary
Noxopharm Limited

-ENDS-



About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome (septic shock).

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunomodulatory functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiation therapies and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, as well as contributing to an anti-cancer action, but also potentially blocking septic shock.

Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of US biotechnology company, Nyrada Inc (ASX:NYR), active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Prue Kelly

M: 0459 022 445

E: info@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@atomicgroup.com.au

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.